Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Mood Disorders, Antipsychotics, and TD

Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss mood disorders, antipsychotics and tardive dyskinesia (TD).
Joseph Goldberg, MD
Roger McIntyre, MD, FRCPC
Released: May 24, 2021

In this episode, Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss tardive dyskinesia (TD), mood disorders, and antipsychotics. They review current clinical considerations and assessments, including whether antipsychotic prescriptions for mood disorders have increased, if patients with mood disorder are at higher risk for TD and why, and when and how to use an AIMS exam, even in telepsychiatry. They also review the evidence base for VMAT2 inhibitors in TD, what nonevidence-based treatments healthcare professionals should avoid, and how to choose between the 2 VMAT2 inhibitors.  

Presenters:

Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Joseph Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant provided by
Neurocrine Biosciences

Related Content

Slides from a presentation that educates clinicians on Huntington disease and the management of chorea

Victor W. Sung, MD Released: September 17, 2021

Slides from a presentation that educates clinicians on strategies to improve mood disorders and tardive dyskinesia (TD) treatment.

Greg Mattingly, MD Released: September 1, 2021

In Neuroscience Research Review (GME Research Review), Drs Gupta and McEvoy respond to current articles on tardive dyskinesia (TD) including pharmacologic treatments and identification via the AIMS exam

Sanjay Gupta, MD Joseph P. McEvoy, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credits Released: August 31, 2021 Expired: August 30, 2022

In Neuroscience Research Review (GME Research Review), Drs Gupta and McEvoy respond to current articles on tardive dyskinesia (TD) including pharmacologic treatments and identification via the AIMS exam

Sanjay Gupta, MD Joseph P. McEvoy, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credits Released: August 31, 2021 Expired: August 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue